Neuronal Nicotinic Receptors - June 2008
Neuronal nicotinic receptor ligands are fast proceeding through clinical development as exciting candidates for multiple CNS disorders including Alzheimer's disease; Schizophrenia; ADHD; Depression; Pain and Adiction.
Are you involved in these areas; are you developing nicotinic receptor ligands? If so UpdatesPlus is for you. This service, brought to you from the pharmaceutical analysts, LeadDiscovery, not only delivers all key breaking research, drug development news and clinical trials in this area, it also analyzes it.
Published monthly along with a fully up to date pipeline of nicotinic receptor therapeutics, UpdatesPlus offers a key insight into the strategy and development within the nicotinics arena. Offering an ideal intelligence tool for everyone from brand managers to medical directors and preclinical managers, UpdatesPlus is a must for all involved in this exciting new field of medicine
See December 2007 edition now (free sample copy)
Table of Contents
What's in the June 2008 edition of UpdatesPlus-Nicotinic Receptors?
-
Key decisions ahead for Memory Pharmaceuticals - MEM 3454 and MEM 63908: LeadDiscovery analysts look at times ahead for Memory Pharmaceutical as the company's second phase 2a study approaches completion. Will MEM 3454 advance into phase 2b for CIAS or Alzheimer's; how will 3454 be positioned against 63908?
-
Pfizer and the continued hunt for α7 ligands: Pfizer have been looking for an α7 clinical candidate ever since development of PHA-543613 ceased.....how are they getting on? Read the latest of their efforts here
-
AstraZeneca prepares to advance TC-5214 - The road to phase 3: Exciting times are ahead for TC-5214. Is ADHD set to join Alzheimer's and CIAS as an indication? What trials have opened in readiness for phase 3? Read LeadDiscovery's views on the current development of TC-5214 and what barriers to success may be on the horizon
-
Targacept continue rapid development of TC-5214 - A new treatment of depression on the horizon? Targacept have been rapidly advancing TC-5214. See how this compound is fast moving towards a much needed option for treatment resistant depression
Pfizer to advance smoking cessation therapeutic, varenicline, as a treatment of cognitive dysfunction? Already a blockbuster as a smoking cesation treatment, are Pfizer about to see the market for varenicline expand further
-
Abbott initiate long term safety study of ABT-089 in adult ADHD. LeadDiscovery analysts lay out the phase 2 program for Abbott's candidate ADHD treatment
Full and up to date pipeline
Pricing & Delivery: UpdatesPlus is available on a subscription basis. A one-off payment will get you the next twelve monthly editions of UpdatesPlus-Nicotinic Receptors plus access to all past editions. UpdatesPlus is available for unlimited use within your company. Delivered in a powerpoint format, UpdatesPlus is both easy to use and also ready for use within a presentation setting
2008 issues:
- January 2008
- February 2008
- March 2008
- April 2008
- May 2008
About UpdatesPlus: Through DailyUpdates, LeadDiscovery has access to one of the most comprehensive sources of information for the drug development sector. UpdatesPlus takes this information and uses our industrial experience to provide a monthly analysis of breaking activity in selected indications and molecular targets. If this is the first time that you have heard of UpdatesPlus please take a moment to have a look at an example. If you would find such a service of use in your area contact us now.
Other users found this report page using the following search terms: Neuronal Nicotinic Receptors nicotinic receptors cognition cognitive cias alzheimer amyloid depression adhd smoking cessation alpha7 alpha6 alpha4beta2 nicotinic ppt receptors receptor neuronal nicotine adhd 2008 alpha7 depression
If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.
Refund and Cancellation Policy: The descriptions of the products and services sold on LeadDiscovery.co.uk are as complete and accurate as possible, and customers are encouraged to read all available information about a product before placing an order. Due to the nature of the information being sold, orders for reports cannot be canceled.